The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors
- Authors
- Koo, Bon San; Lim, Yu-Cheol; Lee, Min-Young; Jeon, Ja-Young; Yoo, Hyun-Jeong; Oh, In-Sun; Shin, Ju-Young; Kim, Tae-Hwan
- Issue Date
- Nov-2021
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Ankylosing spondylitis; herpes zoster; pneumonia; infection; tuberculosis; tumor necrosis factor inhibitor
- Citation
- MODERN RHEUMATOLOGY, v.31, no.6, pp.1192 - 1201
- Indexed
- SCIE
SCOPUS
- Journal Title
- MODERN RHEUMATOLOGY
- Volume
- 31
- Number
- 6
- Start Page
- 1192
- End Page
- 1201
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/140603
- DOI
- 10.1080/14397595.2021.1878985
- ISSN
- 1439-7595
- Abstract
- Objectives
This study aimed to evaluate the risk factor and incidence of infections in patients receiving tumor necrosis factor inhibitor (TNFi) therapy for ankylosing spondylitis using data from the national health insurance service.
Methods
This was a retrospective cohort study. Data regarding patients with ankylosing spondylitis prescribed TNFis were obtained from an insurance claims database of the Health Insurance Review & Assessment Service in Korea. Outcomes used were incidence rates of serious infection, pneumonia, tuberculosis, and herpes zoster during the follow-up period as well as the relationship between each TNFi and sex, hazard ratio (HR) of infection-related risk factors, and incidence of infections.
Results
A total of 2515 patients were included. There were no significant differences among the hazard ratios of TNFis for serious infection, pneumonia, and herpes zoster. However, the hazard ratio of tuberculosis was significantly higher for infliximab than for etanercept (adjusted HR 8.40 [95% confidence interval: 1.06-66.91]). In the subgroup analysis by sex, women treated with golimumab had a significantly higher hazard of herpes zoster than those treated with etanercept (adjusted HR 12.40 [95% confidence interval: 1.40-109.58]).
Conclusion
We recommend that risk factors for these infectious diseases be identified prior to prescribing TNFis in these patients.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/140603)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.